GlassScriptPhysician profile
Alexander Spasic
NPI 1003812132
$17,307.92
in general payments reported to CMS, 2019-2025
47 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $4,626 · 2021: $2,282 · 2022: $2,266 · 2023: $2,627 · 2024: $2,402 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,555.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,830.96 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,552.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,551.92 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,451.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,426.36 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,079.45 | 2019-2025 | Jardiance |
| Pfizer INC. | $918.05 | 2019-2025 | |
| Lilly USA, LLC | $875.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $520.50 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $393.62 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Amgen INC. | $383.99 | 2019-2025 | Otezla, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $313.15 | 2019-2024 | Zoryve, Livalo |
| Janssen Pharmaceuticals, INC | $283.33 | 2019-2024 | Xarelto |
| Ibsa Pharma INC. | $245.21 | 2022-2024 | Tirosint, Licart, Licart |
| Exact Sciences Corporation | $241.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Spasic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.